Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Review

MicroRNAs in B cell development and malignancy

Authors: Thilini R Fernando, Norma I Rodriguez-Malave, Dinesh S Rao

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show profound defects in B cell development; and is also critical at the level of specific miRNAs. In this review, we discuss miRNAs that are involved in normal B cell development in the bone marrow and during B cell activation and terminal differentiation in the periphery. Next, we turn to miRNAs that are dysregulated during diseases of B cells, including malignant diseases and autoimmunity. Further study of miRNAs and their targets will lead to a better understanding of B cell development, and should also lead to the development of novel therapeutic strategies against B cell diseases.
Appendix
Available only for authorised users
Literature
1.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391: 806-811. 10.1038/35888.PubMedCrossRef
2.
Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75: 843-854. 10.1016/0092-8674(93)90529-Y.PubMedCrossRef
3.
Ruvkun G, Giusto J: The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. Nature. 1989, 338: 313-319. 10.1038/338313a0.PubMedCrossRef
4.
Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001, 409: 363-366. 10.1038/35053110.PubMedCrossRef
5.
Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (New York, NY. 2001, 293: 1146-1150. 10.1126/science.1064023.CrossRef
6.
Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH: Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001, 15: 2654-2659. 10.1101/gad.927801.PubMedCentralPubMedCrossRef
7.
Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D: MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol. 2003, 13: 807-818. 10.1016/S0960-9822(03)00287-2.PubMedCrossRef
8.
Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993, 75: 855-862. 10.1016/0092-8674(93)90530-4.PubMedCrossRef
9.
Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009, 10: 126-139. 10.1038/nrm2632.PubMedCrossRef
10.
Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN: MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23: 4051-4060. 10.1038/sj.emboj.7600385.PubMedCentralPubMedCrossRef
11.
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN: The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003, 425: 415-419. 10.1038/nature01957.PubMedCrossRef
12.
Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004, 432: 235-10.1038/nature03120.PubMedCrossRef
13.
Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. Science (New York, NY. 2004, 303: 95-98. 10.1126/science.1090599.CrossRef
14.
15.
Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing. Mol Cell. 2007, 27: 91-105. 10.1016/j.molcel.2007.06.017.PubMedCentralPubMedCrossRef
16.
Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120: 15-20. 10.1016/j.cell.2004.12.035.PubMedCrossRef
17.
18.
19.
Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND et al: A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science (New York, NY. 2010, 328: 1694-1698. 10.1126/science.1190809.CrossRef
20.
Carmell MA, Xuan Z, Zhang MQ, Hannon GJ: The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev. 2002, 16: 2733-2742. 10.1101/gad.1026102.PubMedCrossRef
21.
Sasaki T, Shiohama A, Minoshima S, Shimizu N: Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics. 2003, 82: 323-330. 10.1016/S0888-7543(03)00129-0.PubMedCrossRef
22.
Xu S, Guo K, Zeng Q, Huo J, Lam KP: The RNase III enzyme Dicer is essential for germinal center B-cell formation. Blood. 2012, 119: 767-776. 10.1182/blood-2011-05-355412.PubMedCrossRef
23.
Belver L, de Yebenes VG, Ramiro AR: MicroRNAs prevent the generation of autoreactive antibodies. Immunity. 2010, 33: 713-722. 10.1016/j.immuni.2010.11.010.PubMedCentralPubMedCrossRef
24.
25.
Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM: Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002, 17: 51-62. 10.1016/S1074-7613(02)00335-7.PubMedCrossRef
26.
Hardy RR, Hayakawa K: B cell development pathways. Annu Rev Immunol. 2001, 19: 595-621. 10.1146/annurev.immunol.19.1.595.PubMedCrossRef
27.
Perez-Vera P, Reyes-Leon A, Fuentes-Panana EM: Signaling proteins and transcription factors in normal and malignant early B cell development. Bone marrow research. 2011, 2011: 502751-PubMedCentralPubMedCrossRef
28.
Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD: MicroRNAs: new regulators of immune cell development and function. Nature immunology. 2008, 9: 839-845. 10.1038/ni.f.209.PubMedCrossRef
29.
Nagasawa T: Microenvironmental niches in the bone marrow required for B-cell development. Nature reviews Immunology. 2006, 6: 107-116. 10.1038/nri1780.PubMedCrossRef
30.
Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, Ren CH, Koyama S, Nagasawa H, Kimura H, Kawanami T et al: The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2006, 26: 9227-9238. 10.1523/JNEUROSCI.0341-06.2006.CrossRef
31.
Nussenweig RS: Human trials of malaria vaccine. Science (New York, NY. 1987, 236: 763-CrossRef
32.
Murphy K: Janeway's Immunobiology. Book Janeway's Immunobiology. 2012, City: Garland Science, Taylor & Francis Group, LLC, 8
33.
Nemazee D, Buerki K: Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc Natl Acad Sci USA. 1989, 86: 8039-8043. 10.1073/pnas.86.20.8039.PubMedCentralPubMedCrossRef
34.
Nutt SL, Kee BL: The transcriptional regulation of B cell lineage commitment. Immunity. 2007, 26: 715-725. 10.1016/j.immuni.2007.05.010.PubMedCrossRef
35.
Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, Tucker PW, Rao A: Foxp1 is an essential transcriptional regulator of B cell development. Nature immunology. 2006, 7: 819-826. 10.1038/ni1358.PubMedCrossRef
36.
Kikuchi K, Kondo M: Developmental switch of mouse hematopoietic stem cells from fetal to adult type occurs in bone marrow after birth. Proc Natl Acad Sci USA. 2006, 103: 17852-17857. 10.1073/pnas.0603368103.PubMedCentralPubMedCrossRef
37.
Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, Li D, Durum SK, Jiang Q, Bhandoola A et al: Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA. 2006, 103: 1000-1005. 10.1073/pnas.0507350103.PubMedCentralPubMedCrossRef
38.
Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L, Moriggl R, Sexl V: Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 2006, 107: 4898-4906. 10.1182/blood-2005-09-3596.PubMedCentralPubMedCrossRef
39.
Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, Krop I, Schlissel MS, Feeney AJ, van Roon M et al: E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell. 1994, 79: 885-892. 10.1016/0092-8674(94)90077-9.PubMedCrossRef
40.
Cobaleda C, Schebesta A, Delogu A, Busslinger M: Pax5: the guardian of B cell identity and function. Nature immunology. 2007, 8: 463-470. 10.1038/ni1454.PubMedCrossRef
41.
Lin YC, Jhunjhunwala S, Benner C, Heinz S, Welinder E, Mansson R, Sigvardsson M, Hagman J, Espinoza CA, Dutkowski J et al: A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nature immunology. 2010, 11: 635-643. 10.1038/ni.1891.PubMedCentralPubMedCrossRef
42.
O'Riordan M, Grosschedl R: Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity. 1999, 11: 21-31. 10.1016/S1074-7613(00)80078-3.PubMedCrossRef
43.
Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D: MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity. 2010, 33: 48-59. 10.1016/j.immuni.2010.06.013.PubMedCentralPubMedCrossRef
44.
Look AT: Oncogenic transcription factors in the human acute leukemias. Science. 1997, 278: 1059-1064. 10.1126/science.278.5340.1059.PubMedCrossRef
45.
Smith E, Sigvardsson M: The roles of transcription factors in B lymphocyte commitment, development, and transformation. J Leukoc Biol. 2004, 75: 973-981. 10.1189/jlb.1103554.PubMedCrossRef
46.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007, 446: 758-764. 10.1038/nature05690.PubMedCrossRef
47.
Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene MC, Beldjord K, De Vos J, Dastugue N, Coyaud E, Struski S, Quelen C et al: PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009, 23: 1989-1998. 10.1038/leu.2009.135.PubMedCrossRef
48.
49.
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008, 453: 110-114. 10.1038/nature06866.PubMedCrossRef
50.
Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A, Sensel M, Reaman GH, Uckun FM: Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 1999, 96: 680-685. 10.1073/pnas.96.2.680.PubMedCentralPubMedCrossRef
51.
Nakase K, Ishimaru F, Avitahl N, Dansako H, Matsuo K, Fujii K, Sezaki N, Nakayama H, Yano T, Fukuda S et al: Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. Cancer Res. 2000, 60: 4062-4065.PubMed
52.
Olivero S, Maroc C, Beillard E, Gabert J, Nietfeld W, Chabannon C, Tonnelle C: Detection of different Ikaros isoforms in human leukaemias using real-time quantitative polymerase chain reaction. Br J Haematol. 2000, 110: 826-830. 10.1046/j.1365-2141.2000.02297.x.PubMedCrossRef
53.
Nishii K, Katayama N, Miwa H, Shikami M, Usui E, Masuya M, Araki H, Lorenzo F, Ogawa T, Kyo T et al: Non-DNA-binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia. Leukemia. 2002, 16: 1285-1292. 10.1038/sj.leu.2402533.PubMedCrossRef
54.
Takanashi M, Yagi T, Imamura T, Tabata Y, Morimoto A, Hibi S, Ishii E, Imashuku S: Expression of the Ikaros gene family in childhood acute lymphoblastic leukaemia. Br J Haematol. 2002, 117: 525-530. 10.1046/j.1365-2141.2002.03487.x.PubMedCrossRef
55.
Meleshko AN, Movchan LV, Belevtsev MV, Savitskaja TV: Relative expression of different Ikaros isoforms in childhood acute leukemia. Blood Cells Mol Dis. 2008, 41: 278-283. 10.1016/j.bcmd.2008.06.006.PubMedCrossRef
56.
Mullighan CG, Downing JR: Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol. 2009, 46: 3-15. 10.1053/j.seminhematol.2008.09.005.PubMedCentralPubMedCrossRef
57.
Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A: The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994, 79: 143-156. 10.1016/0092-8674(94)90407-3.PubMedCrossRef
58.
Morgan B, Sun L, Avitahl N, Andrikopoulos K, Ikeda T, Gonzales E, Wu P, Neben S, Georgopoulos K: Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 1997, 16: 2004-2013. 10.1093/emboj/16.8.2004.PubMedCentralPubMedCrossRef
59.
Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005, 19: 652-658.PubMed
60.
Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, Michaux L, Sagaert X, Marynen P, Hagemeijer A, De Wolf-Peeters C: FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia. 2005, 19: 1299-1305. 10.1038/sj.leu.2403813.PubMedCrossRef
61.
62.
Shapiro-Shelef M, Calame K: Regulation of plasma-cell development. Nature reviews Immunology. 2005, 5: 230-242. 10.1038/nri1572.PubMedCrossRef
63.
Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad J, Miljkovic V, Cattoretti G, Califano A, Dalla-Favera R: Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA. 2003, 100: 2639-2644. 10.1073/pnas.0437996100.PubMedCentralPubMedCrossRef
64.
Odegard VH, Schatz DG: Targeting of somatic hypermutation. Nature reviews Immunology. 2006, 6: 573-583. 10.1038/nri1896.PubMedCrossRef
65.
McHeyzer-Williams LJ, McHeyzer-Williams MG: Antigen-specific memory B cell development. Annu Rev Immunol. 2005, 23: 487-513. 10.1146/annurev.immunol.23.021704.115732.PubMedCrossRef
66.
Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, Ludwig T, Rajewsky K, Dalla-Favera R: Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nature immunology. 2006, 7: 773-782. 10.1038/ni1357.PubMedCrossRef
67.
Cambier JC, Gauld SB, Merrell KT, Vilen BJ: B-cell anergy: from transgenic models to naturally occurring anergic B cells?. Nat Rev Immunol. 2007, 7: 633-643. 10.1038/nri2133.PubMedCentralPubMedCrossRef
68.
Bartel DP, Chen CZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004, 5: 396-400.PubMedCrossRef
69.
Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science (New York, NY. 2004, 303: 83-86. 10.1126/science.1091903.CrossRef
70.
Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, Jensen K, Cobb BS, Merkenschlager M, Rajewsky N, Rajewsky K: Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008, 132: 860-874. 10.1016/j.cell.2008.02.020.PubMedCrossRef
71.
Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature immunology. 2008, 9: 405-414. 10.1038/ni1575.PubMedCentralPubMedCrossRef
72.
Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K: MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007, 131: 146-159. 10.1016/j.cell.2007.07.021.PubMedCrossRef
73.
Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF: miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA. 2007, 104: 7080-7085. 10.1073/pnas.0702409104.PubMedCentralPubMedCrossRef
74.
Xiao C, Rajewsky K: MicroRNA control in the immune system: basic principles. Cell. 2009, 136: 26-36. 10.1016/j.cell.2008.12.027.PubMedCrossRef
75.
Meffre E, Casellas R, Nussenzweig MC: Antibody regulation of B cell development. Nature immunology. 2000, 1: 379-385. 10.1038/80816.PubMedCrossRef
76.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D: A microRNA component of the p53 tumour suppressor network. Nature. 2007, 447: 1130-1134. 10.1038/nature05939.PubMedCentralPubMedCrossRef
77.
Chang T-C, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee Kwang H, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ et al: Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes Apoptosis. Molecular Cell. 2007, 26: 745-752. 10.1016/j.molcel.2007.05.010.PubMedCentralPubMedCrossRef
78.
Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB et al: p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes. Curr Biol. 2007, 17: 1298-1307. 10.1016/j.cub.2007.06.068.PubMedCrossRef
79.
O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D: MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA. 2010, 107: 14235-14240. 10.1073/pnas.1009798107.PubMedCentralPubMedCrossRef
80.
Georgantas RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI: CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA. 2007, 104: 2750-2755. 10.1073/pnas.0610983104.PubMedCentralPubMedCrossRef
81.
Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Moller P, Poppema S, Kroesen BJ, van den Berg A: Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia (New York, NY. 2009, 11: 167-176.CrossRef
82.
O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007, 104: 1604-1609. 10.1073/pnas.0610731104.PubMedCentralPubMedCrossRef
83.
Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006, 103: 12481-12486. 10.1073/pnas.0605298103.PubMedCentralPubMedCrossRef
84.
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA et al: Requirement of bic/microRNA-155 for normal immune function. Science (New York, NY. 2007, 316: 608-611. 10.1126/science.1139253.CrossRef
85.
Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A et al: microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007, 27: 847-859. 10.1016/j.immuni.2007.10.009.PubMedCentralPubMedCrossRef
86.
Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN: MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 2008, 28: 621-629. 10.1016/j.immuni.2008.03.015.PubMedCentralPubMedCrossRef
87.
Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, San-Martin BR, Heidkamp G, Schwickert TA et al: MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity. 2008, 28: 630-638. 10.1016/j.immuni.2008.04.002.PubMedCentralPubMedCrossRef
88.
de Yebenes VG, Belver L, Pisano DG, Gonzalez S, Villasante A, Croce C, He L, Ramiro AR: miR-181b negatively regulates activation-induced cytidine deaminase in B cells. The Journal of Experimental Medicine. 2008, 205: 2199-2206. 10.1084/jem.20080579.PubMedCentralPubMedCrossRef
89.
Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J et al: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal of Experimental Medicine. 2011, 208: 1189-1201. 10.1084/jem.20101823.PubMedCentralPubMedCrossRef
90.
Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer BC, Flemington EK: Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol. 2008, 82: 1946-1958. 10.1128/JVI.02136-07.PubMedCentralPubMedCrossRef
91.
Kawai T, Akira S: Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007, 13: 460-469. 10.1016/j.molmed.2007.09.002.PubMedCrossRef
92.
Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D: NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA. 2011, 108: 9184-9189. 10.1073/pnas.1105398108.PubMedCentralPubMedCrossRef
93.
Gururajan M, Haga CL, Das S, Leu CM, Hodson D, Josson S, Turner M, Cooper MD: MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int Immunol. 2010, 22: 583-592. 10.1093/intimm/dxq042.PubMedCentralPubMedCrossRef
94.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M et al: A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 2005, 353: 1793-1801. 10.1056/NEJMoa050995.PubMedCrossRef
95.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002, 99: 15524-15529. 10.1073/pnas.242606799.PubMedCentralPubMedCrossRef
96.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 2004, 101: 2999-3004. 10.1073/pnas.0307323101.PubMedCentralPubMedCrossRef
97.
Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H et al: Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci USA. 2010, 107: 3710-3715. 10.1073/pnas.0914900107.PubMedCentralPubMedCrossRef
98.
Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM: Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006, 103: 7024-7029. 10.1073/pnas.0602266103.PubMedCentralPubMedCrossRef
99.
99. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR et al: Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009, 114: 1374-1382. 10.1182/blood-2009-05-220814.PubMedCentralPubMedCrossRef
100.
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008, 111: 3183-3189. 10.1182/blood-2007-07-098749.PubMedCentralPubMedCrossRef
101.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005, 102: 13944-13949. 10.1073/pnas.0506654102.PubMedCentralPubMedCrossRef
102.
Medina PP, Nolde M, Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010, 467: 86-90. 10.1038/nature09284.PubMedCrossRef
103.
Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE et al: Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011, 305: 59-67. 10.1001/jama.2010.1919.PubMedCentralPubMedCrossRef
104.
Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Durig J, van Oers MH, Mertens D et al: miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009, 113: 3801-3808. 10.1182/blood-2008-08-172254.PubMedCrossRef
105.
Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med. 2005, 352: 804-815. 10.1056/NEJMra041720.PubMedCrossRef
106.
Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grander D, Iyengar A, Baranova A, Kashuba V, Merup M et al: Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene. 1997, 15: 2463-2473. 10.1038/sj.onc.1201643.PubMedCrossRef
107.
107. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV et al: Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001, 97: 2098-2104. 10.1182/blood.V97.7.2098.PubMedCrossRef
108.
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, Dalla-Favera R: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010, 17: 28-40. 10.1016/j.ccr.2009.11.019.PubMedCrossRef
109.
Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J et al: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. International Journal of Cancer. 2007, 121: 1156-1161. 10.1002/ijc.22800.CrossRef
110.
Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M: Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004, 64: 3087-3095. 10.1158/0008-5472.CAN-03-3773.PubMedCrossRef
111.
111. Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH, Chadburn A, Tuschl T, Knowles DM, Tam W: MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. The American Journal of Pathology. 2008, 173: 242-252. 10.2353/ajpath.2008.080009.PubMedCentralPubMedCrossRef
112.
112. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H et al: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010, 18: 367-381. 10.1016/j.ccr.2010.09.005.PubMedCentralPubMedCrossRef
113.
Iborra M, Bernuzzi F, Invernizzi P, Danese S: MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response. Autoimmunity reviews. 2010, 11: 305-314.PubMedCrossRef
114.
Ronnblom L, Eloranta ML, Alm GV: The type I interferon system in systemic lupus erythematosus. Arthritis and rheumatism. 2006, 54: 408-420. 10.1002/art.21571.PubMedCrossRef
115.
Pascual V, Farkas L, Banchereau J: Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol. 2006, 18: 676-682. 10.1016/j.coi.2006.09.014.PubMedCrossRef
116.
Crow MK: Type I interferon in systemic lupus erythematosus. Current topics in microbiology and immunology. 2007, 316: 359-386. 10.1007/978-3-540-71329-6_17.PubMed
117.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP et al: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and rheumatism. 2009, 60: 1065-1075. 10.1002/art.24436.PubMedCrossRef
118.
119.
Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY: Dicer-dependent microRNA pathway safeguards regulatory T cell function. The Journal of experimental medicine. 2008, 205: 1993-2004. 10.1084/jem.20081062.PubMedCentralPubMedCrossRef
120.
Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY: Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009, 30: 80-91. 10.1016/j.immuni.2008.11.010.PubMedCentralPubMedCrossRef
121.
Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY: Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010, 142: 914-929. 10.1016/j.cell.2010.08.012.PubMedCentralPubMedCrossRef
122.
123.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005, 438: 685-689. 10.1038/nature04303.PubMedCrossRef
Metadata
Title
MicroRNAs in B cell development and malignancy
Authors
Thilini R Fernando
Norma I Rodriguez-Malave
Dinesh S Rao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-7

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Rapid communication

Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia

Short report

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

Letter to the Editor

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Review

Clinical applications of mesenchymal stem cells

Review

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Research

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits